Latest Biotech News

UniQure recently reported positive results from its pivotal Phase I/II study of AMT-130, a gene therapy aimed at treating Huntington’s disease. The high-dose treatment demonstrated a statistically...

The FDA has approved Eli Lilly’s Inluriyo (formerly imlunestrant), an oral selective estrogen receptor degrader (SERD), for treating adults with metastatic, estrogen receptor-positive,...

Hansa Biopharma’s imlifidase, an antibody-cleaving enzyme, has yielded positive data from a pivotal U.S. Phase III trial in highly sensitized kidney disease patients. The drug rapidly removes...

Researchers at the Arc Institute have developed and optimized bridge recombinases, versatile RNA-guided enzymes capable of large-scale genome rearrangements in human cells at efficiencies up to...

The Arc Institute unveiled 'Germinal', an AI-driven platform combining AlphaFold-Multimer gradients and antibody language models to design epitope-targeted antibodies with reduced experimental...

Biomedical engineers at Duke University have pioneered a platform that merges automated wet lab protocols with sophisticated artificial intelligence to revolutionize nanoparticle design for drug...

In a major advance against drug-resistant pathogens, researchers from Monash University and The Alfred Hospital engineered bespoke bacteriophage cocktails targeting multidrug-resistant bacterial...

UniQure’s AMT-130 therapy marks a historic milestone as the first intervention to demonstrate a marked 75% slowing in Huntington’s disease progression over three years, according to pivotal...

Scientists led by David Baker’s lab at the University of Washington developed a generalizable molecular switch design that precisely modulates protein-protein binding kinetics, increasing...

Uniqure has announced positive top-line data from the pivotal Phase I/II study of its gene therapy AMT-130 for Huntington's disease, demonstrating a statistically significant 75% slowing in...

Researchers at the Arc Institute have developed a universal bridge recombinase platform that expands gene editing capabilities beyond small mutations to enable large-scale genomic rearrangements...

The FDA has cleared Eli Lilly's oral selective estrogen receptor degrader (SERD) Inluriyo (formerly imlunestrant) for treatment of adults with metastatic, estrogen receptor-positive, HER2-negative...

Pumpkinseed, a Stanford University spinout, is advancing its silicon chip technology that sequences peptides and analyzes immune cell functionality using Raman spectroscopy. Its platform enables...

Hansa Biopharma has reported positive Phase III trial results for imlifidase, an enzyme that rapidly removes anti-HLA antibodies, enabling highly sensitized kidney transplant patients to receive...

Biotechnologist Rachel Ee of the National University of Singapore has developed short self-assembling peptides that form microscopic nets in response to bacterial presence, trapping and killing...

UniQure has achieved a pivotal success in Huntington's disease (HD) gene therapy with its AMT-130 candidate, demonstrating a significant 75% reduction in disease progression at 36 months in a...

Lila Sciences secured $235 million in a Series A round led by Braidwell and Collective Global to scale its AI-driven scientific research platform. The company integrates generative AI, robotics,...

New clinical data from UniQure's AMT-130 gene therapy reveal a substantial slowing of Huntington's disease progression by 75% over three years in treated patients, meeting the primary composite...

Mass General Brigham and Broad Institute researchers deployed comprehensive CRISPR screening across the T cell lifecycle to discover gene knockouts enhancing CAR T cell proliferation, persistence,...

UniQure announced positive topline results from its pivotal Phase I/II trial of AMT-130, a gene therapy for Huntington’s disease, demonstrating a statistically significant 75% slowing in disease...